scholarly journals The Surviving Sepsis Campaign: research priorities for the administration, epidemiology, scoring and identification of sepsis

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Mark E. Nunnally ◽  
Ricard Ferrer ◽  
Greg S. Martin ◽  
Ignacio Martin-Loeches ◽  
Flavia R. Machado ◽  
...  

Abstract Objective To identify priorities for administrative, epidemiologic and diagnostic research in sepsis. Design As a follow-up to a previous consensus statement about sepsis research, members of the Surviving Sepsis Campaign Research Committee, representing the European Society of Intensive Care Medicine and the Society of Critical Care Medicine addressed six questions regarding care delivery, epidemiology, organ dysfunction, screening, identification of septic shock, and information that can predict outcomes in sepsis. Methods Six questions from the Scoring/Identification and Administration sections of the original Research Priorities publication were explored in greater detail to better examine the knowledge gaps and rationales for questions that were previously identified through a consensus process. Results The document provides a framework for priorities in research to address the following questions: (1) What is the optimal model of delivering sepsis care?; (2) What is the epidemiology of sepsis susceptibility and response to treatment?; (3) What information identifies organ dysfunction?; (4) How can we screen for sepsis in various settings?; (5) How do we identify septic shock?; and (6) What in-hospital clinical information is associated with important outcomes in patients with sepsis? Conclusions There is substantial knowledge of sepsis epidemiology and ways to identify and treat sepsis patients, but many gaps remain. Areas of uncertainty identified in this manuscript can help prioritize initiatives to improve an understanding of individual patient and demographic heterogeneity with sepsis and septic shock, biomarkers and accurate patient identification, organ dysfunction, and ways to improve sepsis care.

2020 ◽  
Vol 21 (10) ◽  
pp. 924-925 ◽  
Author(s):  
Roberta Esteves Vieira de Castro ◽  
Daniela Nasu Monteiro Medeiros ◽  
Arnaldo Prata-Barbosa ◽  
Maria Clara de Magalhães-Barbosa

2018 ◽  
Vol 44 (9) ◽  
pp. 1400-1426 ◽  
Author(s):  
Craig M. Coopersmith ◽  
Daniel De Backer ◽  
Clifford S. Deutschman ◽  
Ricard Ferrer ◽  
Ishaq Lat ◽  
...  

2020 ◽  
Vol 21 (2) ◽  
pp. e52-e106 ◽  
Author(s):  
Scott L. Weiss ◽  
Mark J. Peters ◽  
Waleed Alhazzani ◽  
Michael S. D. Agus ◽  
Heidi R. Flori ◽  
...  

2020 ◽  
Vol 46 (S1) ◽  
pp. 1-9 ◽  
Author(s):  
Scott L. Weiss ◽  
Mark J. Peters ◽  
Waleed Alhazzani ◽  
Michael S. D. Agus ◽  
Heidi R. Flori ◽  
...  

2020 ◽  
Vol 46 (S1) ◽  
pp. 10-67 ◽  
Author(s):  
Scott L. Weiss ◽  
Mark J. Peters ◽  
Waleed Alhazzani ◽  
Michael S. D. Agus ◽  
Heidi R. Flori ◽  
...  

2021 ◽  
Vol 13 ◽  
pp. 1759720X2110140
Author(s):  
Conor Magee ◽  
Hannah Jethwa ◽  
Oliver M. FitzGerald ◽  
Deepak R. Jadon

Aims: The ability to predict response to treatment remains a key unmet need in psoriatic disease. We conducted a systematic review of studies relating to biomarkers associated with response to treatment in either psoriasis vulgaris (PsV) or psoriatic arthritis (PsA). Methods: A search was conducted in PubMed, Embase and the Cochrane library from their inception to 2 September 2020, and conference proceedings from four major rheumatology conferences. Original research articles studying pre-treatment biomarker levels associated with subsequent response to pharmacologic treatment in either PsV or PsA were included. Results: A total of 765 articles were retrieved and after review, 44 articles (22 relating to PsV and 22 to PsA) met the systematic review’s eligibility criteria. One study examined the response to methotrexate, one the response to tofacitinib and all the other studies to biologic disease-modifying antirheumatic drugs (DMARDs). Whilst several studies examined the HLA-C*06 allele in PsV, the results were conflicting. Interleukin (IL)-12 serum levels and polymorphisms in the IL-12B gene show promise as biomarkers of treatment response in PsV. Most, but not all, studies found that higher baseline levels of C-reactive protein (CRP) were associated with a better clinical response to treatment in patients with PsA. Conclusion: Several studies have identified biomarkers associated with subsequent response to treatment in psoriatic disease. However, due to the different types of biomarkers, treatments and outcome measures used, firm conclusions cannot be drawn. Further validation is needed before any of these biomarkers translate to clinical practice.


Author(s):  
Francesco Gavelli ◽  
Luigi Mario Castello ◽  
Gian Carlo Avanzi

AbstractEarly management of sepsis and septic shock is crucial for patients’ prognosis. As the Emergency Department (ED) is the place where the first medical contact for septic patients is likely to occur, emergency physicians play an essential role in the early phases of patient management, which consists of accurate initial diagnosis, resuscitation, and early antibiotic treatment. Since the issuing of the Surviving Sepsis Campaign guidelines in 2016, several studies have been published on different aspects of sepsis management, adding a substantial amount of new information on the pathophysiology and treatment of sepsis and septic shock. In light of this emerging evidence, the present narrative review provides a comprehensive account of the recent advances in septic patient management in the ED.


2017 ◽  
Vol 66 (10) ◽  
pp. 1631-1635 ◽  
Author(s):  
◽  
Andre C Kalil ◽  
David N Gilbert ◽  
Dean L Winslow ◽  
Henry Masur ◽  
...  

The Infectious Diseases Society of America elected not to endorse the Surviving Sepsis Campaign Guidelines due to lack of agreement with the Society of Critical Care Medicine regarding specific recommendations related to diagnosis and therapy for patients with apparent or documented sepsis/septic shock.


Sign in / Sign up

Export Citation Format

Share Document